Interview with Sonia Madigan – The Deal Room
Anatara Lifesciences Ltd (ASX:ANR) CEO Steve Lydeamore was recently interviewed by Sonia Madigan – The Deal Room of The Market Herald, answering questions regarding the Company’s capital raise to fund a human clinical study of its gastrointestinal health product (GaRP) in irritable bowel syndrome (IBS), as well as providing an overview of the Company’s achievements and outlook.
Anatara Lifesciences (ASX:ANR) is developing and commercialising a range of gastrointestinal health products focused on animal and human health. The company’s lead product, Gastrointestinal ReProgramming (GaRP), is a microbiome-targeted complementary medicine. The product is designed to address the primary underlying factors associated with gastrointestinal disorders such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD).